Last reviewed · How we verify

ARMLUPEG (PEGFILGRASTIM-UNNE)

LUPIN LTD · FDA-approved approved Quality 0/100

ARMLUPEG (generic name: PEGFILGRASTIM-UNNE) is a Leukocyte Growth Factor [EPC] drug developed by LUPIN LTD. It is currently FDA-approved.

At a glance

Generic namePEGFILGRASTIM-UNNE
SponsorLUPIN LTD
Drug classLeukocyte Growth Factor [EPC]
Therapeutic areaOther
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

Serious adverse events

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ARMLUPEG

What is ARMLUPEG?

ARMLUPEG (PEGFILGRASTIM-UNNE) is a Leukocyte Growth Factor [EPC] drug developed by LUPIN LTD.

Who makes ARMLUPEG?

ARMLUPEG is developed and marketed by LUPIN LTD (see full LUPIN LTD pipeline at /company/lupin-ltd).

What is the generic name of ARMLUPEG?

PEGFILGRASTIM-UNNE is the generic (nonproprietary) name of ARMLUPEG.

What drug class is ARMLUPEG in?

ARMLUPEG belongs to the Leukocyte Growth Factor [EPC] class. See all Leukocyte Growth Factor [EPC] drugs at /class/leukocyte-growth-factor-epc.

What development phase is ARMLUPEG in?

ARMLUPEG is FDA-approved (marketed).

What are the side effects of ARMLUPEG?

Common side effects of ARMLUPEG include Bone pain, Pain in extremity. Serious adverse events: Splenic rupture, Acute respiratory distress syndrome, Serious hypersensitivity reactions, Glomerulonephritis.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing